Improving rates of pneumococcal vaccination on discharge from a tertiary center medical teaching unit: A prospective intervention

Thomas, Chandra M.; Loewen, Andrea; Coffin, Carla; Campbell, Norman R. C.
January 2005
BMC Public Health;2005, Vol. 5 Issue 1, p110
Academic Journal
Background: Pneumococcal disease causes significant morbidity and mortality in at-risk individuals, and is complicated by emerging antibiotic resistance. An effective, safe and cost-effective vaccine is available, but despite this many patients who would benefit from pneumococcal vaccination remain unvaccinated. The purpose of this study was to determine the rates of missed opportunities to provide pneumococcal vaccination to patients being discharged from a tertiary center medical teaching unit and to determine if a nurse coordinator-based intervention would increase rates of pneumococcal vaccination prior to discharge home. Methods: We conducted a prospective, controlled study in the setting of a Medical Teaching Unit at a tertiary care centre to assess the impact of a nurse coordinator based intervention on the rates of vaccination of eligible patients on discharge home. The rates of vaccination during an eight-week usual-care period (February 20 to April 16, 2002) and an eight-week intervention period (April 22 to June 16, 2002) were compared. Results: Prior to the intervention none of thirty-eight eligible patients were vaccinated prior to discharge home from the Medical Teaching Unit. After the intervention 27 (54%) of fifty eligible patients were vaccinated prior to discharge. Conclusion: There are significant missed opportunities to provide pneumococcal vaccination to inpatients who are discharged home from a medical unit. Using a patient care coordinator we were able to significantly improve the rates of vaccination on discharge.


Related Articles

  • Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Pérez-Trallero, E.; Marimon, J. M.; Ercibengoa, M.; Vicente, D.; Pérez-Yarza, E. G. // European Journal of Clinical Microbiology & Infectious Diseases;Jul2009, Vol. 28 Issue 7, p731 

    In the last two decades, an increasing trend in the incidence of pneumococcal disease in Europe has been reported. We investigated the effect of the use of the heptavalent pneumococcal conjugate vaccine (PCV7) in an area of northern Spain, where all recorded cases of invasive pneumococcal...

  • The Challenge of Reducing Invasive Pneumococcal Disease in Indigenous Indian Populations. Vanderkooi, Otto G.; Kellner, James D. // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1247 

    In this article, the author discusses the efficacy of 7-valent pneumococcal conjugate vaccine (PCV7) in treating indigenous children suffering from invasive pneumococcal infections in the U.S. and Australia. The author notes the effectiveness of the said treatment to the non-indigenous people...

  • New Pneumococcal Vaccine in High-Risk Children. Walling, Anne D. // American Family Physician;3/15/2004, Vol. 69 Issue 6, p1529 

    Presents the results of a study which examined the effectiveness of pneumococcal vaccine in high-risk children to pneumococcal disease in the U.S. Administration of control vaccine for Neisseria meningitis; Dosage of vaccine in community groups; Efficiency of pneumococcal vaccine conjugate PnCRM7.

  • Kenya marks the global roll out of pneumococcal vaccine.  // Africa Health;Mar2011, Vol. 33 Issue 3, p9 

    The article reports on the celebration of the global roll out of vaccines against pneumococcal disease in Kenya on February 14, 2011. It shows that President Mwai Kibaki has joined parents, health workers,and donors in Nairobi to witness children being immunised as part of the government's...

  • Pneumococcal Immunization: From Policy to Practice. Schwartz, Benjamin; Breiman, Robert F. // JAMA: Journal of the American Medical Association;9/5/90, Vol. 264 Issue 9, p1154 

    Editorial. Deals with the low utilization of pneumococcal vaccines targeted for adults in the U.S. Factors behind the lack of use of pneumococcal vaccines; Strategies that can be adopted to increase utilization of pneumococcal vaccines; Cost benefits of immunization.

  • New children's vaccines, new direction. Kassianos, George // GP: General Practitioner;1/12/2007, p30 

    The article focuses on issues related to the introduction of routine immunization of infants against pneumococcal disease in Great Britain. The new immunization schedule was announced on June 12, 2006. One of the problems of introducing a new vaccine is how to fit another vaccine into the...

  • Studies support wider use of pneumococcal vaccine.  // Practice Nurse;1/16/2004, Vol. 27 Issue 1, p6 

    Focuses on a study suggesting that vaccinating children against pneumococcal disease could provide greater benefit than previously thought. Comments from David McIntosh, Honorary Clinical Senior Lecturer at Imperial College in London, England; Guidelines on the use of the vaccine Prevenar;...

  • Adult immunizations: Underused in primary care. Russell, John; Godek, Brent // Patient Care for the Nurse Practitioner;Jul2003, Vol. 6 Issue 7, p6 

    The article focuses on adult immunizations. The decline in mortality from many infectious diseases is directly linked to the use of vaccines. The purified polysaccharide vaccine is 60% to 70% effective overall in the prevention of invasive pneumococcal disease. The influenza vaccine is indicated...

  • General considerations.  // WHO Technical Report Series;2004, Issue 927, p66 

    The article focuses on polysaccharide vaccines for infections caused by Streptococcus pneumoniae, which are responsible for substantial morbidity and mortality, commonly on children and the elderly. Pneumociccus are classified based on chemical and serological distinct capsular polysaccharides....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics